Conduit Pharmaceuticals Inc. Market Cap ($2.84K)
Market Cap & Net Worth: Conduit Pharmaceuticals Inc. (CDT)
Conduit Pharmaceuticals Inc. market cap. Conduit Pharmaceuticals Inc. (NASDAQ:CDT) has a market capitalization of $2.84K ($2.84K) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31952 globally and #6436 in its home market, demonstrating a -46.15% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Conduit Pharmaceuticals Inc.'s stock price $0.07 by its total outstanding shares 40541 (40.54K). Also see Conduit Pharmaceuticals Inc. (CDT) cash conversion ratio for how efficiently the company converts equity into cash flow.
Conduit Pharmaceuticals Inc. Market Cap History (2022–2026)
Conduit Pharmaceuticals Inc. market cap history from 2022 to 2026. Data shows change from $415.55K to $2.84K (-65.93% CAGR). Check CDT live share price for real-time trading data and today's change.
Index Memberships
Conduit Pharmaceuticals Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.00% | #928 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #2922 of 3165 |
Weight: Conduit Pharmaceuticals Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Conduit Pharmaceuticals Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Conduit Pharmaceuticals Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Conduit Pharmaceuticals Inc. to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Conduit Pharmaceuticals Inc.'s market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $2.78K | $922.22 Million | -$17.80 Million | 0.00x | N/A |
| 2025 | $51.89K | $2.72 Billion | -$39.22 Million | 0.00x | N/A |
Competitor Companies of CDT by Market Capitalization
Companies near Conduit Pharmaceuticals Inc. in the global market cap rankings as of November 4, 2026. Also see how large is Conduit Pharmaceuticals Inc.'s balance sheet for a full breakdown of the balance sheet.
Key companies related to Conduit Pharmaceuticals Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Conduit Pharmaceuticals Inc. (2022–2026)
Market capitalization of Conduit Pharmaceuticals Inc. from 2022 to today. Between 2022 and today, Conduit Pharmaceuticals Inc.'s market cap moved from $415.55K to $ 2.84K, with a yearly change of -65.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.84K | -94.53% |
| 2025 | $51.89K | +1765.89% |
| 2024 | $2.78K | -98.49% |
| 2023 | $184.46K | -55.61% |
| 2022 | $415.55K | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Conduit Pharmaceuticals Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.84K USD |
| MoneyControl | $2.84K USD |
| MarketWatch | $2.84K USD |
| marketcap.company | $2.84K USD |
| Reuters | $2.84K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Conduit Pharmaceuticals Inc.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the tre… Read more